BioSpace News Archive

Avalyn Pharma Inc. announced four leadership appointments across the organization, including lung disease drug development expert Craig Conoscenti, M.D., FCCP, ATSF, who will serve as senior vice president, clinical development.

Pliant Therapeutics, Inc. presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Lunit is set to unveil seven significant abstracts at the Radiological Society of North America (RSNA) 2023 Annual Meeting, taking place from November 26 to November 30 in Chicago.

Avertix Medical, Inc. today announced that Tim Moran, President and Chief Executive Officer, and Philip Tom, EVP and Chief Financial Officer, are scheduled to attend the BTIG Digital Health Forum on November 20, 2023.

NorthStar Medical Radioisotopes , LLC, today announced that it will participate in the upcoming 2023 Truist Securities Biopharma Symposium being held November 8 to 9, 2023, in New York, NY.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced results from the Phase 2 clinical study evaluating the “extra-strength” 40U dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), the only neurotoxin dedicated exclusively to aesthetics.

Laxxon Medical announced its participation in the 29th annual BIO-Europe Convention, taking place November 6-8, 2023 in Munich, Germany.

Faron Pharmaceuticals Ltd. announces that based on guidance from the U.S. Food and Drug Administration, hypomethylating agents -refractory or relapsed myelodysplastic syndromes has been selected as the initial indication to advance to Phase 2 in the BEXMAB study investigating bexmarilimab in combination with standard of care.